Recently, Mecp2 re-expression using adeno-associated viral vectors prolonged lifespan and ameliorated behavioral abnormalities associated with RTT in mouse models [38], opening a real possibility for gene therapy to treat RTT. This evidence concerns the gene MECP2 and Rett syndrome.